| 产品编号 | 图片 | CAS No. | 名称及描述 | 规格 | 价格 | 分子式 | 快速订购 |
|---|---|---|---|---|---|---|---|
| GC31315-5g |
|
9002-96-4 |
Tocofersolan (D-α-Tocopherol polyethylene glycol 1000 succinate) - Glpbio |
0 | 需询价 | C35H58O6 | |
| GC31315-10mM(1mLinDMSO) |
|
9002-96-4 |
Tocofersolan (D-α-Tocopherol polyethylene glycol 1000 succinate) - Glpbio |
0 | 需询价 | C35H58O6 | |
| GC31314-5mg |
|
19891-51-1 |
Nagilactone B - Glpbio |
0 | 需询价 | C19H24O7 | |
| GC31314-1mg |
|
19891-51-1 |
Nagilactone B - Glpbio |
0 | 需询价 | C19H24O7 | |
| GC31313-20mg |
|
153874-14-7 |
S16961 (S169611) - Glpbio |
0 | 需询价 | C41H71NO6 | |
| GC31313-10mg |
|
153874-14-7 |
S16961 (S169611) - Glpbio |
0 | 需询价 | C41H71NO6 | |
| GC31313-5mg |
|
153874-14-7 |
S16961 (S169611) - Glpbio |
0 | 需询价 | C41H71NO6 | |
| GC31313-1mg |
|
153874-14-7 |
S16961 (S169611) - Glpbio |
0 | 需询价 | C41H71NO6 | |
| GC31312-100mg |
|
108237-91-8 |
RCGD423 - Glpbio |
0 | 需询价 | C15H11BrN2S | |
| GC31312-50mg |
|
108237-91-8 |
RCGD423 - Glpbio |
0 | 需询价 | C15H11BrN2S | |
| GC31312-25mg |
|
108237-91-8 |
RCGD423 - Glpbio |
0 | 需询价 | C15H11BrN2S | |
| GC31312-10mg |
|
108237-91-8 |
RCGD423 - Glpbio |
0 | 需询价 | C15H11BrN2S | |
| GC31312-5mg |
|
108237-91-8 |
RCGD423 - Glpbio |
0 | 需询价 | C15H11BrN2S | |
| GC31312-10mM(1mLinDMSO) |
|
108237-91-8 |
RCGD423 - Glpbio |
0 | 需询价 | C15H11BrN2S | |
| GC31311-20mg |
|
1254699-12-1 |
Neurodegenerative Disorder-Targeting Compound 1 - Glpbio |
0 | 需询价 | C28H28N4O4 | |
| GC31311-10mg |
|
1254699-12-1 |
Neurodegenerative Disorder-Targeting Compound 1 - Glpbio |
0 | 需询价 | C28H28N4O4 | |
| GC31311-5mg |
|
1254699-12-1 |
Neurodegenerative Disorder-Targeting Compound 1 - Glpbio |
0 | 需询价 | C28H28N4O4 | |
| GC31311-1mg |
|
1254699-12-1 |
Neurodegenerative Disorder-Targeting Compound 1 - Glpbio |
0 | 需询价 | C28H28N4O4 | |
| GC31310-20mg |
|
935840-13-4 |
H3 receptor antagonist 1 - Glpbio |
0 | 需询价 | C20H28F2N2O | |
| GC31310-10mg |
|
935840-13-4 |
H3 receptor antagonist 1 - Glpbio |
0 | 需询价 | C20H28F2N2O | |
小泰
|
010-60710855
|